Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1987-2-26
|
pubmed:abstractText |
Thromboxane (Tx) A2 is a biologically potent and chemically unstable metabolite of prostaglandin endoperoxides. Recent developments in measurement techniques and the availability of both selective inhibitors of Tx synthetase and TxA2 receptor antagonists have facilitated the implication of TxA2 as a physiological modulator and as a mediator in thrombotic, vasospastic, and bronchospastic conditions. TxA2 is synthesized by platelets and contributes to platelet activation and irreversible platelet aggregation in physiological hemostasis and in thrombosis (e.g., unstable angina, stroke). TxA2 is also synthesized in intestinal, pulmonary, and renal tissues by cells other than platelets. Particularly in these tissues, TxA2 appears to act as a physiological modulator of changes in blood flow distribution and airway caliber. Strong stimuli for TxA2 release from these tissues may initiate ulcer, pulmonary hypertension, bronchoconstriction, and renal vasoconstriction. Evidence supports participation of TxA2 and/or TxA2 receptors in modulation of natural cytotoxic cell cytotoxicity, in tumor growth and metastasis, in complications of pregnancy (e.g., preeclampsia), and in the progression of ischemic injury after coronary artery occlusion. This evidence supports pivotal involvement of TxA2 in pathophysiology and provides a strong rationale for pursuing TxA2-blocking strategies in drug development.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin Endoperoxides,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Prostaglandin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thromboxane,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane A2,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane-A Synthase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0014-9446
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
133-8
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2948837-Animals,
pubmed-meshheading:2948837-Blood Platelets,
pubmed-meshheading:2948837-Bronchial Spasm,
pubmed-meshheading:2948837-Cardiovascular Diseases,
pubmed-meshheading:2948837-Hemostasis,
pubmed-meshheading:2948837-Humans,
pubmed-meshheading:2948837-Muscle, Smooth,
pubmed-meshheading:2948837-Muscle Contraction,
pubmed-meshheading:2948837-Platelet Aggregation,
pubmed-meshheading:2948837-Prostaglandin Endoperoxides,
pubmed-meshheading:2948837-Receptors, Prostaglandin,
pubmed-meshheading:2948837-Receptors, Thromboxane,
pubmed-meshheading:2948837-Thrombosis,
pubmed-meshheading:2948837-Thromboxane A2,
pubmed-meshheading:2948837-Thromboxane-A Synthase,
pubmed-meshheading:2948837-Vasoconstriction
|
pubmed:year |
1987
|
pubmed:articleTitle |
Overview of physiological and pathophysiological effects of thromboxane A2.
|
pubmed:publicationType |
Journal Article,
Review
|